Search

The most recent Ebola virus outbreak in West Africa, which was unprecedented in the number of cases and fatalities, geographic distribution, and number of nations affected, highlights the need for [...]

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.ahj.2004.09.056 Byline: Scott D. Solomon (a), Hicham Skali (a), Mikhail Bourgoun (a), James Fang (a), Jalal K. Ghali (b), Michel Martelet (c), Dariusz Wojciechowski (d), Baiba Ansmite (e), Janis Skards (f), Toivo Laks (g), David Henry (h), Milton Packer (i), Marc A. Pfeffer (a) Abstract: Angiotensin-converting enzyme (ACE) inhibition attenuates ventricular remodeling and improves ventricular function in heart failure patients. Vasopeptidase inhibition has shown similar effects in experimental models. Author Affiliation: (a) Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass (b) Cardiac Centers of Louisiana, Shreveport, La (c) C.H. De Langres, Service De Cardiologie, Langres, Cedex, France (d) Ul. Kasprzaka 17, Warszawa, Poland (e) Hospital Linezers, Riga, Latvia (f) Linezers Hospital, Medicine Academy of Latvia, Riga, Latvia (g) Tallinn Central Hospital, Tallinn, Estonia (h) Bristol Myers Squibb, P.O. Box 4000, Princeton, NJ (i) Columbia Presbyterian Medical Center, Milstein Pavilion, New York, NY Article History: Received 18 June 2004; Accepted 24 September 2004 Article Note: (miscellaneous) This study was supported by a research grant from Bristol Myers Squibb.

Byline: Massimo Romano, Stefania Cardei, Elisabetta de Arcangelis, Ida Monteforte, Marianunzia Capaldo, Pietro Muto, Raffaele Marchegiano, Michael Ochan Kilama, Mario Condorelli Abstract: Treatment of abnormal remodeling and dysfunction of left ventricle after myocardial infarction is one of the major goals of recent therapeutic interventions. The current study, the Nisoldipine Enalapril Anterior Myocardial Infarction Study pilot investigation, was designed to investigate the effects of 12 weeks of treatment with enalapril or nisoldipine or their combination on left ventricular (LV) function and exercise capacity in patients with recent ( Author Affiliation: Naples and Milan, Italy Article Note: (footnote) [star] From the Cardiopulmonary Stress Laboratory, I Clinica Medica; Nuclear Medicine, University Federico II; Instituto dei Tumori, Naples; and Bayer Spa, Milan., [star][star] Reprint requests: Massimo Romano, MD, Universita Degli Studi, I. Clinica Medica, Via Pansini 5, 80131 Naples, Italy., a 0002-8703/97/$5.00 + 0 4/1/77771

Researchers used antibiotic chloramphenicol as a model drug to explore prodrug stimulation through antibodies. According to the conformational variation between substrate and product, the antibody-catalyzed reaction was developed to avoid product inhibition and improve turnover. Only the antibody hydrolytically stimulates the monoestor used, which can be an appropriate prodrug because of its resistance to the action of bacterial hydrolytic enzymes.

A new concept directly using drug molecules to fabricate nanocarriers in order to minimize use of inert materials, substantially increase the drug loading content, and suppress premature burst release is described. The concept directly using drugs as part of a carrier could be applied to fabricate other highly efficient nanocarriers with a substantially reduced use of inert carrier materials and increased drug loading content without premature burst release.